Medtronic (Dublin) seems determined to climb back up on the renal denervation horse. The company has kicked off a new clinical feasibility study that will combine pulmonary vein isolation (PVI) and renal denervation for the treatment of paroxysmal or persistent atrial fibrillation (AF), compared to PVI alone.